RANDOMIZED, MULTICENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本方案将在接受尸体或活体供者初次肾移植的0 - 21岁儿科受试者中比较无类固醇免疫抑制剂联合阿托伐他汀（他克莫司）、骁悉（MMF）和赛尼哌（达利珠单抗）诱导与基于类固醇的免疫抑制剂的安全性和疗效。主要疗效终点是1年时标准身高变化的差异;主要安全性结局是12个月时活检证实的急性排斥反应的发生率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol will compare the safety and efficacy of steroid-free immunosuppression, given in combination with Prograf (tacrolimus), CellCept (MMF) and Zenapax (daclizumab) induction with steroid-based immunosuppression in pediatric subjects, ages 0 to 21 years, receiving a primary kidney transplant from a cadaveric or living donor. The primary efficacy endpoint is the difference in the change of standardized height at one year; the primary safety outcome is the rate at 12 months of biopsy proven acute rejection.